{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05226871",
            "orgStudyIdInfo": {
                "id": "A5481173"
            },
            "secondaryIdInfos": [
                {
                    "id": "2021-005735-22",
                    "type": "EUDRACT_NUMBER"
                }
            ],
            "organization": {
                "fullName": "Pfizer",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies",
            "officialTitle": "A TREATMENT PROTOCOL FOR PARTICIPANTS CONTINUING FROM PFIZER-SPONSORED PALBOCICLIB CLINICAL STUDIES",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "study-for-participants-continuing-from-pfizer-sponsored-palbociclib-a-study-medicine-studies"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-07-07",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-12-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-12-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-01-26",
            "studyFirstSubmitQcDate": "2022-01-26",
            "studyFirstPostDateStruct": {
                "date": "2022-02-07",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-22",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-24",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Pfizer",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this clinical trial is to provide study medicine(s) and learn about their safety. This study is seeking participants who:\n\n* Have benefited from ongoing study treatment as determined by the study doctor in a Pfizer-sponsored palbociclib Parent Study\n* Must agree to follow the reproductive criteria\n* Are willing and able to comply with all scheduled visits, treatment plans, and other study procedures\n* Can give signed informed consent documents\n\nParticipants in this study will continue to receive treatment as they were in the parent study. The time by which participants will take part in this study is retrospective (after completed parent study). We will examine the experiences of people receiving the study medicine(s). This will help us determine if the study medicine(s) are safe. During this time, the participants will be monitored for the safety of the study medicine(s).",
            "detailedDescription": "This is an open-label study to provide continued access to treatment for eligible participants who continue to derive clinical benefit as determined by the investigator from study intervention(s) in a Pfizer-sponsored palbociclib clinical study (Parent Study)"
        },
        "conditionsModule": {
            "conditions": [
                "Breast Cancer",
                "Head and Neck Cancer"
            ],
            "keywords": [
                "Hormone Receptor Positive Advanced Breast Cancer",
                "Squamous Cell Carcinoma of the Head and Neck"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 35,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Arm 1",
                    "type": "OTHER",
                    "description": "Cetuximab",
                    "interventionNames": [
                        "Drug: Cetuximab"
                    ]
                },
                {
                    "label": "Arm 2",
                    "type": "EXPERIMENTAL",
                    "description": "Palbociclib plus Cetuximab",
                    "interventionNames": [
                        "Drug: Palbociclib",
                        "Drug: Cetuximab"
                    ]
                },
                {
                    "label": "Arm 3",
                    "type": "OTHER",
                    "description": "Palbociclib plus Fulvestrant",
                    "interventionNames": [
                        "Drug: Palbociclib",
                        "Drug: Fulvestrant"
                    ]
                },
                {
                    "label": "Arm 4",
                    "type": "OTHER",
                    "description": "Palbociclib plus Letrozole",
                    "interventionNames": [
                        "Drug: Palbociclib",
                        "Drug: Letrozole"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Palbociclib",
                    "description": "oral",
                    "armGroupLabels": [
                        "Arm 2",
                        "Arm 3",
                        "Arm 4"
                    ],
                    "otherNames": [
                        "IBRANCE"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Cetuximab",
                    "description": "Intravenous (IV) infusion",
                    "armGroupLabels": [
                        "Arm 1",
                        "Arm 2"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Fulvestrant",
                    "description": "Intramuscular (IM)",
                    "armGroupLabels": [
                        "Arm 3"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Letrozole",
                    "description": "oral",
                    "armGroupLabels": [
                        "Arm 4"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number/Percentage of Participants with Treatment-Emergent Adverse Events (AEs) Leading to Permanent Discontinuation of Study Treatment and Serious Adverse Events (SAEs)",
                    "description": "An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state.",
                    "timeFrame": "Baseline up to 28 days after last dose of study intervention"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Any participant who is receiving study treatment and deriving clinical benefit as determined by the investigator in a Pfizer-sponsored palbociclib Parent Study\n* Participants must agree to follow the reproductive criteria\n* Participants who are willing and able to comply with all scheduled visits, treatment plans, and other study procedures\n* Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent document and protocol\n\nExclusion Criteria:\n\n* Any medical reason that, in the opinion of the investigator or sponsor, precludes the participant from inclusion in the study",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Pfizer CT.gov Call Center",
                    "role": "CONTACT",
                    "phone": "1-800-718-1021",
                    "email": "ClinicalTrials.gov_Inquiries@pfizer.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Pfizer CT.gov Call Center",
                    "affiliation": "Pfizer",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "UCSF Medical Center at Mission Bay",
                    "status": "RECRUITING",
                    "city": "San Francisco",
                    "state": "California",
                    "zip": "94158",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 37.77493,
                        "lon": -122.41942
                    }
                },
                {
                    "facility": "National Cancer Center",
                    "status": "RECRUITING",
                    "city": "Goyang-si",
                    "state": "Gyeonggi-do",
                    "zip": "10408",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 37.65639,
                        "lon": 126.835
                    }
                },
                {
                    "facility": "Samsung Medical Center",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "state": "Seoul-teukbyeolsi [seoul]",
                    "zip": "06351",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Seoul National University Hospital",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "zip": "03080",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Hospital Universitario \"Dr. Jose Eleuterio Gonzalez\"",
                    "status": "RECRUITING",
                    "city": "Monterrey",
                    "state": "Nuevo LE\u00d3N",
                    "zip": "64460",
                    "country": "Mexico",
                    "geoPoint": {
                        "lat": 25.67507,
                        "lon": -100.31847
                    }
                },
                {
                    "facility": "Mackay Memorial Hospital",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Taipei",
                    "zip": "10449",
                    "country": "Taiwan",
                    "geoPoint": {
                        "lat": 25.04776,
                        "lon": 121.53185
                    }
                },
                {
                    "facility": "Regional Municipal Non-profit Enterprise \"Bukovinian Clinical Oncology Center\"",
                    "status": "RECRUITING",
                    "city": "Chernivtsi",
                    "state": "Chernivetska Oblast",
                    "zip": "58013",
                    "country": "Ukraine",
                    "geoPoint": {
                        "lat": 48.29149,
                        "lon": 25.94034
                    }
                },
                {
                    "facility": "Municipal Non-profit Enterprise \"City Clinical Hospital #4\" of Dnipro City Council",
                    "status": "RECRUITING",
                    "city": "Dnipro",
                    "zip": "49102",
                    "country": "Ukraine",
                    "geoPoint": {
                        "lat": 48.4593,
                        "lon": 35.03864
                    }
                },
                {
                    "facility": "Municipal non-profit enterprise Regional Clinical Hospital of Ivano-Frankivsk Regional Council",
                    "status": "RECRUITING",
                    "city": "Ivano-Frankivsk",
                    "zip": "76000",
                    "country": "Ukraine",
                    "geoPoint": {
                        "lat": 48.9215,
                        "lon": 24.70972
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "To obtain contact information for a study center near you, click here.",
                    "url": "https://pmiform.com/clinical-trial-info-request?StudyID=A5481173"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",
            "url": "https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000006258",
                    "term": "Head and Neck Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5220",
                    "name": "Breast Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M1689",
                    "name": "Squamous Cell Carcinoma of Head and Neck",
                    "relevance": "LOW"
                },
                {
                    "id": "M5550",
                    "name": "Carcinoma, Squamous Cell",
                    "relevance": "LOW"
                },
                {
                    "id": "M9348",
                    "name": "Head and Neck Neoplasms",
                    "asFound": "Head and Neck Cancer",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000068818",
                    "term": "Cetuximab"
                },
                {
                    "id": "D000077289",
                    "term": "Letrozole"
                },
                {
                    "id": "D000077267",
                    "term": "Fulvestrant"
                },
                {
                    "id": "C000500026",
                    "term": "Palbociclib"
                }
            ],
            "ancestors": [
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000047072",
                    "term": "Aromatase Inhibitors"
                },
                {
                    "id": "D000065088",
                    "term": "Steroid Synthesis Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000004965",
                    "term": "Estrogen Antagonists"
                },
                {
                    "id": "D000006727",
                    "term": "Hormone Antagonists"
                },
                {
                    "id": "D000006730",
                    "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018931",
                    "term": "Antineoplastic Agents, Hormonal"
                },
                {
                    "id": "D000065171",
                    "term": "Estrogen Receptor Antagonists"
                },
                {
                    "id": "D000047428",
                    "term": "Protein Kinase Inhibitors"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M9789",
                    "name": "Hormones",
                    "relevance": "LOW"
                },
                {
                    "id": "M1743",
                    "name": "Letrozole",
                    "asFound": "Cross-",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1723",
                    "name": "Fulvestrant",
                    "asFound": "Challenge",
                    "relevance": "HIGH"
                },
                {
                    "id": "M223893",
                    "name": "Palbociclib",
                    "asFound": "Red",
                    "relevance": "HIGH"
                },
                {
                    "id": "M315",
                    "name": "Cetuximab",
                    "asFound": "Physician",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M25769",
                    "name": "Aromatase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M8116",
                    "name": "Estrogens",
                    "relevance": "LOW"
                },
                {
                    "id": "M8114",
                    "name": "Estrogen Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M30483",
                    "name": "Estrogen Receptor Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M9788",
                    "name": "Hormone Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M20966",
                    "name": "Antineoplastic Agents, Hormonal",
                    "relevance": "LOW"
                },
                {
                    "id": "M25820",
                    "name": "Protein Kinase Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                }
            ]
        }
    },
    "hasResults": false
}